The Cologuard test - Exact Sciences leans on at-home colon cancer screening

Cologuard test from Exact Sciences screens for colorectal cancer in average-risk adults using a stool DNA sample collected at home and sent to a certified lab. Anyone holding Exact Sciences stock (NASDAQ: EXAS, ISIN US30063P1057) should know this product.

By Catherine Berg, ad hoc news Classics & Longsellers Desk. Reviewed July 05, 2026, 2:11 AM ET. Details in the imprint.

Cologuard test kits from Exact Sciences arrive in a plain white box that looks more like a coffee maker than a medical device, but inside is a full at-home colorectal cancer screening setup that many US primary care doctors now prescribe as an alternative to a first colonoscopy. You open the lid and there’s a plastic collection container, a blue preservative solution, a prepaid return label, and a simple instruction booklet with diagrams that feel closer to Ikea than a hospital. That tactile experience of snapping the container onto a toilet seat, hearing it click into place, and sealing the sample feels strangely empowering for patients who dread the sterile chill of a GI lab.

At-home colorectal screening

Cologuard is an FDA-approved stool DNA test designed for adults ages 45 and older at average risk for colorectal cancer, offering a noninvasive option instead of an initial colonoscopy for many patients in the US. The test looks for specific DNA markers and occult blood associated with colorectal cancer and advanced adenomas in a single stool sample collected at home, then shipped to Exact Sciences’ laboratory for analysis. According to the company’s Cologuard patient information, the kit can be ordered only with a prescription, typically from a primary care physician or gastroenterologist.

The test’s clinical performance has made it a staple in colorectal cancer prevention conversations: in pivotal studies cited by Exact Sciences, Cologuard demonstrated approximately 92% sensitivity for detecting colorectal cancer and 42% sensitivity for advanced precancerous lesions in average-risk adults, with a specificity around 87%. Independent coverage by Mayo Clinic’s overview of stool DNA testing notes that stool DNA tests like Cologuard are recommended every three years, compared with a ten-year interval for colonoscopies in average-risk patients.

How the Cologuard process works

Once a physician submits an electronic order, Exact Sciences contacts the patient to confirm shipping details, insurance coverage, and any contraindications such as a history of colorectal cancer, inflammatory bowel disease, or certain genetic syndromes that would push the patient toward colonoscopy instead. The box arrives at the patient’s home within a few days in most US ZIP codes, with the contents clearly labeled; the company’s step-by-step guide emphasizes that the stool sample should be collected promptly and mailed back the same day to maintain integrity of DNA markers. On their Exact Sciences Cologuard overview, the firm states that most test results are available to the ordering provider within two weeks.

Inside the laboratory, technicians use automated workflows to isolate DNA from the stool sample and apply assays that detect methylated DNA biomarkers, mutant KRAS, and hemoglobin, among other targets. A proprietary algorithm then combines these marker signals into a single positive or negative result for colorectal neoplasia risk. Speaking at a recent investor presentation, Exact Sciences CEO Kevin Conroy described the lab process as “scalable high-complexity testing that lets us handle hundreds of thousands of samples annually without sacrificing turnaround time” – emphasizing the industrial scale behind a kit that looks very simple on a bathroom shelf.

US pricing, coverage and access

For US consumers, the most practical question is cost. Exact Sciences lists the list price of Cologuard at around $681, but most commercially insured patients and many Medicare beneficiaries pay far less out-of-pocket because the test is covered as a preventive service. The Centers for Medicare & Medicaid Services (CMS) approved coverage for Cologuard in 2014 as part of colorectal cancer screening for eligible beneficiaries, and commercial insurers gradually followed; by now, Cologuard is widely reimbursed for average-risk adults aged 45 to 85 if ordered according to labeling. As detailed by CMS coverage documentation, certain high-risk patients are excluded because they require colonoscopy.

Patient-facing materials emphasize that Exact Sciences checks insurance coverage before shipping the kit and provides financial assistance for eligible patients who are uninsured or underinsured. A detailed breakdown on Cologuard’s insurance and cost page explains that many patients pay $0 under preventive screening benefits, but co-pays and deductibles still apply for some plans. For US retail investors, the scale of this covered population – tens of millions of adults in the target age range – is central to understanding Cologuard’s revenue potential.

Position versus colonoscopy and other tests

Cologuard does not replace colonoscopy, which remains the gold standard for colorectal cancer screening and allows simultaneous detection and removal of polyps. Instead, guidelines from organizations such as the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society position stool-based tests like Cologuard as alternative screening options in shared decision-making with patients who may decline colonoscopy. A summary by the American Cancer Society lists stool DNA tests alongside annual fecal immunochemical tests (FIT) and high-sensitivity guaiac tests.

In practice, many US clinicians see Cologuard as a way to get hesitant patients into the screening system. Family medicine physician Dr. Lisa Hernandez, who has spoken publicly about her use of Cologuard in a Midwestern practice, describes telling patients: “If you cannot tolerate the idea of a colonoscopy right now, I would rather you do an at-home DNA test every few years than do nothing at all.” That behavioral angle – the trade between clinical ideal and real-world adherence – is a big part of why Exact Sciences has pushed hard to make the kit feel approachable, from the homey packaging to the clear instructions.

Operational scale and data

On the operational side, Exact Sciences has built a centralized lab infrastructure to process Cologuard samples at scale. Company filings indicate that the firm has run millions of Cologuard tests since launch, with volumes rising as screening guidelines lowered the starting age from 50 to 45. In its most recent annual report, Exact Sciences highlighted Cologuard as a major contributor to revenue, citing growth in completed tests and repeat usage among existing patient cohorts. Public coverage by outlets like Reuters on Exact Sciences earnings has repeatedly pointed to strong demand for Cologuard as a key driver of top-line performance.

For clinicians and health systems, the appeal is that Exact Sciences handles logistics end-to-end. Providers place electronic orders, the company ships kits directly to patients, the lab processes samples, and results flow back into electronic health records. That reduces friction compared with older stool tests that required manual forms and local handling. Health systems that partner with Exact Sciences also gain aggregated data on screening rates and positivity, which can inform population health strategies and quality metrics tied to reimbursement.

Investor angle and stock link

For US retail investors, Cologuard is more than a medical product; it is a recurring revenue engine built around a long-term public health need. Colorectal cancer remains one of the most commonly diagnosed cancers in the United States, and large payers have strong incentives to maintain preventive screening programs that lower late-stage treatment costs. The fact that Cologuard fits into covered preventive benefits for many patients, and can be repeated every three years, gives Exact Sciences a durable stream of test volume that is less cyclical than discretionary procedures.

Exact Sciences, headquartered in Madison, Wisconsin, is a diagnostics-focused biotech company that also markets Oncotype DX breast cancer tests and is developing additional multi-cancer detection platforms. Shares of Exact Sciences (NASDAQ: EXAS) trade in US dollars on the Nasdaq, with Cologuard forming a central pillar of the company’s revenue and investor narrative around early cancer detection.

Key facts on Cologuard

• Product: Cologuard test
• Manufacturer: Exact Sciences Corp.
• Category: Classics & longsellers colorectal cancer screening test
• Launch: FDA approval and US market introduction in 2014
• MSRP / Price: Approx. $681 list price in the US, with typical out-of-pocket costs lower depending on insurance coverage
• Availability: Prescription-only stool DNA test available to average-risk adults aged 45 and older across the United States
• Target audience: Adults at average risk for colorectal cancer who prefer a noninvasive, at-home screening option instead of an initial colonoscopy
• Standout / USP: FDA-approved at-home stool DNA test that combines multiple biomarkers and occult blood detection to offer high sensitivity for colorectal cancer in a single, mail-in sample

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.